CONTACT: Maria Gordon Shydlo/Melanie Nadeau
Padilla Speer Beardsley
(212) 752-8338

FOR IMMEDIATE RELEASE

TOPOTARGET ENHANCES TOTECT™ REPLACEMENT KIT POLICY
− New Six-Year Replacement Kit Policy –
− Totect™ the Only FDA-Approved Treatment for Anthracycline Extravasation –

ROCKAWAY, N.J. (February 5, 2008) – TopoTarget USA, Inc., the U.S. subsidiary of TopoTarget A/S, a Denmark-based biotechnology firm specializing in cancer treatments, enhanced and extended its replacement kit policy to six years for Totect™ (dexrozoxane for injection) on all kits purchased, effective immediately. Totect™ is the only treatment approved by the U.S. Food and Drug Administration (FDA) for extravasation from intravenous anthracycline chemotherapy, the accidental leakage of chemotherapy drugs into surrounding healthy tissue.

"While Totect™ has only been available for a few months, cancer centers have already begun adopting this Orphan and patent-protected drug therapy and we have reports of successful outcomes following the use of this treatment," said John Parsons, president of the U.S. subsidiary and global chief commercial officer. "As part of our on-going discussions with physicians, nurses and pharmacists, we have seen an opportunity to significantly extend the Totect™ replacement kit policy, which should accelerate stocking of this emergency treatment kit. Totect™ has a high degree of efficacy and must be used as soon as possible within the first six hours of detection of an anthracycline extravasation."

TopoTarget's initial replacement kit policy allowed for a replacement kit at no cost if the initial purchased Totect™ kit was not used before its expiration date. The new enhanced policy is applicable to all TopoTarget customers who purchased a Totect™ Emergency Treatment Kit(s)

– more –

since its launch on October 16, 2007. Through this enhanced replacement kit policy, purchasers are guaranteed free replacement of Totect™ kits for a period of six years from date of purchase on all kits, thus maximizing the purchaser's investment in this emergency anthracycline extravasation treatment.

More than 500,000 doses of intravenous anthracycline chemotherapy are administered in the United States each year. Each time an anthracycline is administered, either intravenously or via a port, the risk of extravasation exists. Left untreated, extravasation with an anthracycline can lead to severe tissue and cumulative tissue necrosis including serious damage to the surrounding skin, subcutaneous tissue, muscle and nerve. Many patients who have experienced an anthracycline extravasation need surgery to remove the damaged tissue and usually require plastic surgery. In addition, a patient may not be able to continue with chemotherapy until the damaged area heals.

Contraindications: None known. Warnings: Pregnancy Category D. Precautions: Totect™ is a cytotoxic drug. When administered to patients receiving anthracycline-containing cytotoxic therapy, additive cytotoxicity may occur. Treatment with Totect™ is associated with leucopenia, neutropenia, and thrombocytopenia. Hematological monitoring should be performed. Reversible elevations of liver enzymes may occur with dexrozoxane. Patients with Moderate or Severe Renal Insufficiency: Greater exposure to dexrozoxane may occur in patients with compromised renal function. The Totect™ dose should be reduced by 50% in patients with creatinine clearance values <40mL/min. Dimethylsulfoxide (DMSO) should not be used in patients who are receiving dexrozoxane to treat anthracycline-induced extravasation. Laboratory Tests: Blood counts and liver enzymes should be monitored. Adverse Reactions: Dexrazoxane has been studied previously as a cytotoxic agent. Adverse reactions of nausea/vomiting, diarrhea, stomatitis, bone marrow suppression (neutropenia, thrombocytopenia), altered liver function (increased AST/ALT), and infusion site burning have been observed. These adverse reactions have been reversible.

TopoTarget USA, Inc., has invested in an extensive education program to raise awareness of anthracycline extravasations, including prevention, early detection and use of the only FDA-

approved treatment – Totect™. TopoTarget oncology specialists in 10 U.S. geographical regions have conducted more than 21 educational seminars since September 6, 2007 and have already scheduled 20 events for the first half 2008.

TopoTarget USA, Inc., recently leased additional space in its U.S.-based headquarters in Rockaway, N.J., as it continues to expand its operations. The company currently has oncology specialists covering the continental United States and Hawaii, and provides support for reimbursement and medical information.

For general information on Totect™, you may visit www.totect.com or call (866) 914-2922. To order Totect™, please call (800) 746-6273. Full prescribing information, including clinical trial information, safety, dosing, drug interactions and contraindications is available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails and search for Totect™.

About TopoTarget

TopoTarget (OMX: TOPO) is a biotechnology company, headquartered in Denmark with subsidiaries in the United States, Switzerland, Germany and the United Kingdom, dedicated to finding "answers for cancer" and developing improved cancer therapies. TopoTarget was founded and is run by clinical cancer specialists, and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. The company focuses on highly predictive cancer models and key cancer targets (including HDACi, NAD+, mTOR, FASligand and topoisomerase II inhibitors) and has built a strong development foundation. TopoTarget has a broad portfolio of small molecule preclinical drug candidates and eight drugs (both small molecules and protein-based) are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene™/Totect™ was approved by the European Medicines Agency (EMEA) in 2006 and the FDA in 2007, respectively, and is TopoTarget's first product on the market. For more information, go to www.topotarget.com.

###

TopoTarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. TopoTarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: the risk that any one or more of the drug development programs of TopoTarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment issues or based on new information from non-clinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; TopoTarget's history of incurring losses and the uncertainty of achieving profitability; TopoTarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against TopoTarget's products, processes and technologies; the ability to protect TopoTarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability exposure. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.